It looked like the wildfires in Los Angeles could force STS to cancel its annual meeting, but the group worked with city officials and was able to carry on as planned. STS President Jennifer C. Romano, MD, MS, discussed that difficult decision and previewed the three-day event in a new interview.

Rakesh Gopinathannair, MD, lead author of a recent American Heart Association scientific statement on cardiac arrhythmias associated with COVID-19, reviewed the latest science associated with this important topic.

Stephen Browning, the FDA's assistant director of hemodynamics and heart failure diagnostics, spoke with Cardiovascular Business about the agency's perspective on AI-enabled cardiovascular devices and many other topics.

Rebecca Hahn, MD, discussed key takeaways from the TRISCEND II trial for the Edwards Lifesciences Evoque TTVR valve and shared additional details related to patient selection and implanting the device.

"This research should be a call to health systems, policymakers and other stakeholders to make it easier for patients—especially the most vulnerable patients—to access PAD-specific care," one cardiologist explained. 

Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.

Heart Rhythm Society President Kenneth A. Ellenbogen, MD, detailed a new advocacy group focused on improving EP reimbursements, patient care and access. “If you’re not at the table, you’re on the menu," he said.

Robotic-assisted mitral valve repair is associated with short-term outcomes comparable to conventional surgery, according to a new analysis of more than 40,000 patients. Robotic treatment also helps patients spend less time in the hospital, but the costs are much higher.